EN DE
Watch Zhejiang Taimei Med Tech Co for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zhejiang Taimei Med Tech Co (2576) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Zhejiang Taimei Med Tech Co stock HK$3.77, price HK$4.52, that is 16.5% below the price, quality 55 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

ZT Zhejiang Taimei Med Tech Co logo Thin data Nov 10, 2026

Zhejiang Taimei Med Tech Co

2576 · HK

Expensive (fair value 17% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Quality 55/100 
Price moving sideways (no uptrend) 
Fair value HK$3.77 · Overvalued 
Weak Growth (revenue 3y −3.1 %/yr in CNY) 
Loss-making · -12.3% net margin (TTM) 
Negative free cash flow 
Trails peers (2/9) 
Narrow moat 11/100 · thin data
Thin data 
Estimate
Watch Zhejiang Taimei Med Tech Co for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$9.20 HK$3.10 Fair Value HK$3.77 Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

25‑month range HK$3.10 – HK$9.20 · fair‑value band HK$2.83 – HK$4.72 · the HK$4.52 price screens above the HK$3.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Zhejiang Taimei Med Tech Co in your weekly email

Every Wednesday you see whether Zhejiang Taimei Med Tech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally.

Show moreShow less

The company offers Wiz.AI, an AI platform for clinical trials; TrialOS pharmaceutical R&D collaboration platform; PharmaOS, a pharmaceutical digital marketing platform; and the enterprise-medical academic interaction platform.

It also provides pharmaceutical R&D solutions comprising eCollect, eBalance, eCooperate, eArchives, eImage medical imaging evaluation system, eSMS site management system, Paylite financial management system, and eCollege training management system; TrialPartner digital SMO services, IRC independent review center solutions, and eSAE clinical trial safety information management system; eSitePro clinical trial management platform, eTrialPro research ward management system, GCP-X intelligent clinical trial platform, IIT-EDC research data collection system, eScreening subject information management system, eMonitoring intelligent remote monitoring system, and IDS investigational drug services; and IDCT intelligent decentralized clinical trial.

In addition, the company offers eSafety pharmacovigilance compliance management system; eSAE clinical trial safety information management system; ONECEM omni-channel marketing platform, such as ONECEM-SFE sales operation system, ONECEM-SCRM intelligent marketing system, and ONECEM-event+engagement system; and ONEInsight marketing data platform, including boundless corporate medical interaction platform.

Further, it provides research and development support; technical, clinical operation, data management, statistical analysis, and management services; independent image evaluation services; and pharmaceutical marketing and institution digitalization solutions.

The company was formerly known as Jiaxing Taimei Medical Technology Co., Ltd. Zhejiang Taimei Medical Technology Co., Ltd.was founded in 2013 and is headquartered in Jiaxing, China.

Stock analysis

Zhejiang Taimei Med Tech Co (2576) currently trades at HK$4.52, while our estimate is HK$3.77, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$2.83 (bear) to HK$4.72 (bull), the price of HK$4.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Zhejiang Taimei Med Tech Co reported revenue of 499M CNY in FY2025 versus 466M CNY in FY2021, a compound +1.7%/yr. Reported net income was −41.7M CNY in FY2025.

Key figures

Market cap HK$2.5B (≈ $324M) Small · P/S ratio 4.37 · Net margin −8.4% · Return on equity −5.9% · Return on assets (EBIT) −19.9% (5-year average) · Operating margin −12.9% · Revenue (TTM) 532M CNY · Revenue growth (YoY) +8.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −17%, 2576 screens cheaper than that median.

Fair Value

Bear HK$2.83 Fair Value HK$3.77 Bull HK$4.72
Price HK$4.52 · Downside -16.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 29
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−173.1% (2020) → −12.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2576 screens overvalued: fair value 17% below the price. Compare with Veeva Systems Inc →

Compare Zhejiang Taimei Med Tech Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 142 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −16.5% · Below median
Profitability
Return on assets −2.7% · Below median
Net margin (12 months) −12.3% · Below median
Operating margin (12 months) −12.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 8.0% · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 1.93× · Cheaper than median
P/S (12 months) 4.06× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 16
FUTURE (revenue growth)40 · sector 43
PAST (return on equity)0 · sector 3
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $301.53 $332.66 +10% vs 2576
Doximity, Inc DOCS $33.34 $36.54 +10% vs 2576
HealthEquity, Inc HQY $103.46 $113.36 +10% vs 2576
Waystar Holding WAY $27.99 $29.10 +4% vs 2576
Tempus AI, Inc TEM $71.60 $52.58 −27% vs 2576
HeartFlow, Inc HTFL $48.46 $30.56 −37% vs 2576
Hinge Health, Inc HNGE $115.39 $51.25 −56% vs 2576
Pro Medicus Limited PME A$202.57 A$85.12 −58% vs 2576
BrightSpring Health Services, Inc BTSG $71.21 $25.72 −64% vs 2576
XtalPi Holdings 2228 HK$5.87 HK$1.53 −74% vs 2576

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhejiang Taimei Med Tech Co: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zhejiang Taimei Med Tech Co Fair Value". https://www.fairvalue-calculator.com/stock/2576

Frequently asked questions

Is Zhejiang Taimei Med Tech Co (2576) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$3.77 versus a price of HK$4.52, about 17% lower (overvalued).
What is the fair value of 2576?
Our estimate for Zhejiang Taimei Med Tech Co is HK$3.77 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$4.52.
What is the quality score of 2576?
Zhejiang Taimei Med Tech Co has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Taimei Med Tech Co (2576)?
Our calculated price target is the estimate of HK$3.77 (as of Nov 10, 2026). Cautious scenario HK$2.83, optimistic scenario HK$4.72. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Zhejiang Taimei Med Tech Co stock forecast for 2026?
Our estimate puts fair value at HK$3.77, about 17% lower versus a price of HK$4.52 (overvalued). Cautious scenario HK$2.83, optimistic scenario HK$4.72. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Taimei Med Tech Co (2576)?
Zhejiang Taimei Med Tech Co reported trailing-twelve-month revenue of about 532M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Zhejiang Taimei Med Tech Co (2576)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Taimei Med Tech Co it is HK$3.77 per share (as of Nov 10, 2026), against a price of HK$4.52.
Is Zhejiang Taimei Med Tech Co stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2576 trades above its calculated fair value: price HK$4.52, fair value HK$3.77, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2576?
No. The price is what the market pays today (HK$4.52); the fair value is what the company's own numbers justify (HK$3.77). For Zhejiang Taimei Med Tech Co the two are HK$0.7450 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Taimei Med Tech Co worth?
The market values Zhejiang Taimei Med Tech Co at about HK$2.5B (market capitalisation, as of Nov 10, 2026). Per share that is HK$4.52; our models calculate a fair value of HK$3.77 per share.
What do the bullish and bearish scenarios say about 2576?
Our models span a range for Zhejiang Taimei Med Tech Co: cautious scenario HK$2.83, base HK$3.77, optimistic HK$4.72 per share (as of Nov 10, 2026, price HK$4.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang Taimei Med Tech Co (2576)?
Balance-sheet figures for Zhejiang Taimei Med Tech Co (as of Nov 10, 2026): return on equity −5.9%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 2576 from its 52-week high?
Zhejiang Taimei Med Tech Co trades at HK$4.52, about 40% below its 52-week high of HK$7.50 and 21% above the low of HK$3.73 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.77 is for.
Which stocks are comparable to Zhejiang Taimei Med Tech Co?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Taimei Med Tech Co stock attractive at the current price?
The data as of Nov 10, 2026: price HK$4.52, calculated fair value HK$3.77 (−17%), Quality Score 55/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Zhejiang Taimei Med Tech Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Taimei Med Tech Co (2576)?
The closing price on Nov 13, 2026 was HK$4.52. Our estimate is HK$3.77, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Taimei Med Tech Co right now?
Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Zhejiang Taimei Med Tech Co

How large is the market capitalisation of Zhejiang Taimei Med Tech Co (2576)?
The market capitalisation of Zhejiang Taimei Med Tech Co is HK$2.5B (≈ $324M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Taimei Med Tech Co (2576)?
The price-to-sales ratio of Zhejiang Taimei Med Tech Co is 4.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Zhejiang Taimei Med Tech Co (2576)?
The net margin of Zhejiang Taimei Med Tech Co is −8.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Taimei Med Tech Co (2576)?
The return on equity (ROE) of Zhejiang Taimei Med Tech Co is −5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Taimei Med Tech Co (2576)?
On an EBIT basis the return on assets of Zhejiang Taimei Med Tech Co is −19.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Taimei Med Tech Co (2576)?
The operating margin of Zhejiang Taimei Med Tech Co is −12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Taimei Med Tech Co (2576)?
Revenue at Zhejiang Taimei Med Tech Co is growing 8.0% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Zhejiang Taimei Med Tech Co (2576) generate?
The free cash flow of Zhejiang Taimei Med Tech Co is −43.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Taimei Med Tech Co (2576) hold?
Zhejiang Taimei Med Tech Co holds more cash than debt, 392M CNY net (balance sheet 30 Jun 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Zhejiang Taimei Med Tech Co in the live analysis

One click puts Zhejiang Taimei Med Tech Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.